"The implications are that a certain class of CaMKII activity inhibitors actually could be used chronically to treat brain conditions including Alzheimer's disease," said Bayer, senior author of the study. "This is super novel, as it has previously been thought that any CaMKII activity inhibitor would block synaptic plasticity that underlies learning and memory so their chronic use would be counter-indicated."